abstract: UNASSIGNED: Nuclear hormone receptor liver X receptor-alpha (LXRa) has a vital role in @entity2 homeostasis and is reported to have a role in adipose function and @entity1 although this is controversial. Conversely, mesenchymal stem cells (MSCs) are suggested to be a major source of adipocyte generation. Accordingly, we examined the role of LXRa in adipogenesis of MSCs. Adult @entity0 MSCs (mMSCs) were isolated from wild-type (WT) and @entity6 -null @entity0 . Using WT mMSCs, we further generated cell lines stably overexpressing GFP-LXRa (mMSC/LXRa/GFP) or GFP alone (mMSC/GFP) by @entity4 . Confluent mMSCs were differentiated into adipocytes by the established protocol. Compared with MSCs isolated from WT @entity0 , MSCs from @entity6 -null @entity0 showed significantly increased adipogenesis, as determined by lipid droplet accumulation and adipogenesis-related gene expression. Moreover, mMSCs stably overexpressing GFP-LXRa (mMSC/LXRa/GFP) exhibited significantly decreased adipogenesis compared with mMSCs overexpressing GFP alone (mMSC/GFP). Since Wnt/ @entity5 signaling is reported to inhibit adipogenesis, we further examined it. The @entity6 -null group showed significantly decreased Wnt expression accompanied by a decrease of cellular @entity5 (vs WT). The mMSC/LXRa/GFP group exhibited significantly increased Wnt expression accompanied by an increase of cellular @entity5 (vs mMSC/GFP). These data demonstrate that LXRa has an inhibitory effect on adipogenic differentiation in mMSCs with Wnt/ @entity5 signaling. These results provide important insights into the pathophysiology of @entity1 and @entity1 -related consequences such as @entity3 and may identify potential therapeutic targets.Laboratory Investigation advance online publication, 23 November 2015; doi:10.1038/labinvest.2015.141.

title: Nuclear hormone receptor LXRa inhibits adipocyte differentiation of mesenchymal stem cells with Wnt/ XXXX signaling.

answer: @entity5


abstract: INTRODUCTION: Financial management skills-that is, the skills needed to handle personal finances such as banking and paying bills-are essential to a @entity0 's autonomy, independence, and community living. To date, no comprehensive review of financial management skills instruments exists, making it difficult for clinicians and researchers to choose relevant instruments. The objectives of this review are to: (a) identify all available instruments containing financial management skill items that have been used with adults with acquired @entity1 ; (b) categorize the instruments by source (i.e., observation based, self-report, proxy report); and (c) describe observation-based performance instruments by populations, overarching concepts measured, and comprehensiveness of financial management items. Objective (c) focuses on observation-based performance instruments as these measures can aid in situations where the @entity0 with @entity1 has poor self-awareness or where the proxy has poor knowledge of the @entity0 's current abilities. METHOD: Two reviewers completed two systematic searches of five databases. Instruments were categorized by reviewing published literature, copies of the instruments, and/or communication with instrument authors. @entity4 was based on nine key domains of financial management skills developed by the authors. RESULTS: A total of 88 discrete instruments were identified. Of these, 44 were categorized as observation-based performance and 44 as self- and/or proxy-reports. Of the 44 observation-based performance instruments, 8 had been developed for acquired @entity3 populations and 24 for aging and @entity2 populations. Only 7 of the observation-based performance instruments had items spanning 6 or more of the 9 financial management skills domains. CONCLUSIONS: The majority of instruments were developed for aging and @entity2 populations, and few were comprehensive. This review provides foundation for future instrument psychometric and clinimetric reviews. It a necessary first step in providing information to support decision making for clinicians and researchers selecting financial management skills instruments.

title: Identifying instruments to quantify financial management skills in adults with acquired XXXX .

answer: @entity1


abstract: BACKGROUND: Lay involvement in implementation of research evidence into practice may include using research findings to guide individual care, as well as involvement in research processes and policy development. Little is known about the conditions required for such involvement. AIM: To assess @entity1 survivors' research awareness, use of research evidence in their own care and readiness to be involved in research processes. METHODS: Cross sectional survey of @entity1 survivors participating in population-based @entity1 registers in six European centres. RESULTS: The response rate was 74% (481/647). Reasons for participation in register research included responding to clinician request (56%) and to 'give something back' (19%); however, 20% were unaware that they were participating in a @entity1 register. Research awareness was generally low: 57% did not know the purpose of the register they had been recruited to; 73% reported not having received results from the register they took part in; 60% did not know about any research on @entity1 care. Few @entity0 (7.6%) used research evidence during their consultations with a doctor. The 34% of @entity0 who were interested in being involved in research were younger, more highly educated and already research aware. CONCLUSIONS: Across Europe, @entity1 survivors already participating in research appear ill informed about @entity1 research. Researchers, healthcare professionals and @entity0 associations need to improve how research results are communicated to @entity0 populations and research @entity0 , and to raise awareness of the relationship between research evidence and increased quality of care.

title: XXXX engagement with research: European population register study.

answer: @entity0


abstract: BACKGROUND: @entity3 is a common complication of @entity1 therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. The objective of this study was to examine @entity3 prevalence among @entity1 survivors and to characterize changes in clinical outcomes and costs associated with a defined therapeutic intervention (use of a @entity2 [ @entity2 ]) in a representative, privately insured population. METHODS AND FINDINGS: Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013. @entity0 were required to have 12 months of continuous insurance coverage prior to @entity2 receipt (baseline), as well as a 12-month follow-up period. Analyses were performed for individuals with @entity1 -related @entity3 (n=1,065). @entity3 prevalence was calculated: number of @entity0 with a @entity3 in a calendar year divided by total number of enrollees. The impact of @entity2 use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, @entity2 receipt. @entity3 prevalence among @entity1 survivors increased from 0.95% in 2007 to 1.24% in 2013. @entity2 use was associated with decreases in rates of hospitalizations (45% to 32%, p<0.0001), outpatient hospital visits (95% to 90%, p<0.0001), cellulitis diagnoses (28% to 22%, p=0.003), and physical therapy use (50% to 41%, p<0.0001). The average baseline health care costs were high ( 53,422) but decreased in the year after @entity2 acquisition (- 11,833, p<0.0001). CONCLUSIONS: @entity3 is a prevalent medical condition that is often a defining attribute of @entity1 survivorship. The problem is associated with high health care costs; Treatment (in this instance, use of @entity2 ) is associated with significant decreases in adverse clinical outcomes and costs.

title: XXXX prevalence and treatment benefits in @entity1 : impact of a therapeutic intervention on health outcomes and costs.

answer: @entity3


abstract: BACKGROUND: @entity3 is a common complication of @entity1 therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. The objective of this study was to examine @entity3 prevalence among @entity1 survivors and to characterize changes in clinical outcomes and costs associated with a defined therapeutic intervention (use of a @entity2 [ @entity2 ]) in a representative, privately insured population. METHODS AND FINDINGS: Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013. @entity0 were required to have 12 months of continuous insurance coverage prior to @entity2 receipt (baseline), as well as a 12-month follow-up period. Analyses were performed for individuals with @entity1 -related @entity3 (n=1,065). @entity3 prevalence was calculated: number of @entity0 with a @entity3 in a calendar year divided by total number of enrollees. The impact of @entity2 use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, @entity2 receipt. @entity3 prevalence among @entity1 survivors increased from 0.95% in 2007 to 1.24% in 2013. @entity2 use was associated with decreases in rates of hospitalizations (45% to 32%, p<0.0001), outpatient hospital visits (95% to 90%, p<0.0001), cellulitis diagnoses (28% to 22%, p=0.003), and physical therapy use (50% to 41%, p<0.0001). The average baseline health care costs were high ( 53,422) but decreased in the year after @entity2 acquisition (- 11,833, p<0.0001). CONCLUSIONS: @entity3 is a prevalent medical condition that is often a defining attribute of @entity1 survivorship. The problem is associated with high health care costs; Treatment (in this instance, use of @entity2 ) is associated with significant decreases in adverse clinical outcomes and costs.

title: @entity3 prevalence and treatment benefits in XXXX : impact of a therapeutic intervention on health outcomes and costs.

answer: @entity1


abstract: UNASSIGNED: @entity5 ( @entity7 ) is an addictive drug that can cause @entity1 and @entity0 . Several pieces of evidence have demonstrated that @entity7 @entity1 results in increases in oxidative stress that regulate an intracellular signaling cascade that leads to cell death. Recently, several studies have emphasized that the overload of cytosolic @entity2 levels and mitochondrial fission into a small mitochondrial structure is involved in cell death processes. In the present study, we aimed to investigate the effects of @entity7 @entity1 on cytosolic @entity2 overload and mitochondrial fission in @entity3 SH-SY5Y cells. Additionally, the protective effect of @entity6 against @entity7 -induced @entity1 was also investigated. The results of the present study demonstrated that @entity7 significantly decreases cell viability and increases the levels of mitochondrial fission ( @entity9 and @entity8 ) proteins and pro-apoptotic protein, @entity4 in isolated mitochondria. The levels of @entity8 in the cytosol of @entity7 -treated cells had no significant differences compared to the control untreated cells. @entity7 also significantly increased the cytosolic @entity2 levels. @entity6 reversed the toxic effects of @entity7 by restoring cell viability and inhibiting the increase in mitochondrial @entity9 levels and the mitochondrial translocation of @entity8 and @entity4 . Additionally, @entity6 was able to reduce the @entity7 -induced increase in cytosolic @entity2 levels and fragmented mitochondria into small globular structures in SH-SY5Y cells. The results of the present study demonstrate the potential abilities of @entity6 to maintain the homeostasis of mitochondrial dynamics and cytosolic @entity2 levels in @entity7 -induced @entity1 in neuronal cells.

title: @entity6 attenuates the mitochondrial translocation of mitochondrial fission proteins and @entity4 , cytosolic @entity2 overload and cell death in @entity5 -induced XXXX in @entity3 SH-SY5Y cells.

answer: @entity1


abstract: UNASSIGNED: @entity5 ( @entity7 ) is an addictive drug that can cause @entity1 and @entity0 . Several pieces of evidence have demonstrated that @entity7 @entity1 results in increases in oxidative stress that regulate an intracellular signaling cascade that leads to cell death. Recently, several studies have emphasized that the overload of cytosolic @entity2 levels and mitochondrial fission into a small mitochondrial structure is involved in cell death processes. In the present study, we aimed to investigate the effects of @entity7 @entity1 on cytosolic @entity2 overload and mitochondrial fission in @entity3 SH-SY5Y cells. Additionally, the protective effect of @entity6 against @entity7 -induced @entity1 was also investigated. The results of the present study demonstrated that @entity7 significantly decreases cell viability and increases the levels of mitochondrial fission ( @entity9 and @entity8 ) proteins and pro-apoptotic protein, @entity4 in isolated mitochondria. The levels of @entity8 in the cytosol of @entity7 -treated cells had no significant differences compared to the control untreated cells. @entity7 also significantly increased the cytosolic @entity2 levels. @entity6 reversed the toxic effects of @entity7 by restoring cell viability and inhibiting the increase in mitochondrial @entity9 levels and the mitochondrial translocation of @entity8 and @entity4 . Additionally, @entity6 was able to reduce the @entity7 -induced increase in cytosolic @entity2 levels and fragmented mitochondria into small globular structures in SH-SY5Y cells. The results of the present study demonstrate the potential abilities of @entity6 to maintain the homeostasis of mitochondrial dynamics and cytosolic @entity2 levels in @entity7 -induced @entity1 in neuronal cells.

title: @entity6 attenuates the mitochondrial translocation of mitochondrial fission proteins and @entity4 , cytosolic @entity2 overload and cell death in XXXX -induced @entity1 in @entity3 SH-SY5Y cells.

answer: @entity5


abstract: UNASSIGNED: @entity5 ( @entity7 ) is an addictive drug that can cause @entity1 and @entity0 . Several pieces of evidence have demonstrated that @entity7 @entity1 results in increases in oxidative stress that regulate an intracellular signaling cascade that leads to cell death. Recently, several studies have emphasized that the overload of cytosolic @entity2 levels and mitochondrial fission into a small mitochondrial structure is involved in cell death processes. In the present study, we aimed to investigate the effects of @entity7 @entity1 on cytosolic @entity2 overload and mitochondrial fission in @entity3 SH-SY5Y cells. Additionally, the protective effect of @entity6 against @entity7 -induced @entity1 was also investigated. The results of the present study demonstrated that @entity7 significantly decreases cell viability and increases the levels of mitochondrial fission ( @entity9 and @entity8 ) proteins and pro-apoptotic protein, @entity4 in isolated mitochondria. The levels of @entity8 in the cytosol of @entity7 -treated cells had no significant differences compared to the control untreated cells. @entity7 also significantly increased the cytosolic @entity2 levels. @entity6 reversed the toxic effects of @entity7 by restoring cell viability and inhibiting the increase in mitochondrial @entity9 levels and the mitochondrial translocation of @entity8 and @entity4 . Additionally, @entity6 was able to reduce the @entity7 -induced increase in cytosolic @entity2 levels and fragmented mitochondria into small globular structures in SH-SY5Y cells. The results of the present study demonstrate the potential abilities of @entity6 to maintain the homeostasis of mitochondrial dynamics and cytosolic @entity2 levels in @entity7 -induced @entity1 in neuronal cells.

title: XXXX attenuates the mitochondrial translocation of mitochondrial fission proteins and @entity4 , cytosolic @entity2 overload and cell death in @entity5 -induced @entity1 in @entity3 SH-SY5Y cells.

answer: @entity6


abstract: UNASSIGNED: @entity5 ( @entity7 ) is an addictive drug that can cause @entity1 and @entity0 . Several pieces of evidence have demonstrated that @entity7 @entity1 results in increases in oxidative stress that regulate an intracellular signaling cascade that leads to cell death. Recently, several studies have emphasized that the overload of cytosolic @entity2 levels and mitochondrial fission into a small mitochondrial structure is involved in cell death processes. In the present study, we aimed to investigate the effects of @entity7 @entity1 on cytosolic @entity2 overload and mitochondrial fission in @entity3 SH-SY5Y cells. Additionally, the protective effect of @entity6 against @entity7 -induced @entity1 was also investigated. The results of the present study demonstrated that @entity7 significantly decreases cell viability and increases the levels of mitochondrial fission ( @entity9 and @entity8 ) proteins and pro-apoptotic protein, @entity4 in isolated mitochondria. The levels of @entity8 in the cytosol of @entity7 -treated cells had no significant differences compared to the control untreated cells. @entity7 also significantly increased the cytosolic @entity2 levels. @entity6 reversed the toxic effects of @entity7 by restoring cell viability and inhibiting the increase in mitochondrial @entity9 levels and the mitochondrial translocation of @entity8 and @entity4 . Additionally, @entity6 was able to reduce the @entity7 -induced increase in cytosolic @entity2 levels and fragmented mitochondria into small globular structures in SH-SY5Y cells. The results of the present study demonstrate the potential abilities of @entity6 to maintain the homeostasis of mitochondrial dynamics and cytosolic @entity2 levels in @entity7 -induced @entity1 in neuronal cells.

title: @entity6 attenuates the mitochondrial translocation of mitochondrial fission proteins and XXXX , cytosolic @entity2 overload and cell death in @entity5 -induced @entity1 in @entity3 SH-SY5Y cells.

answer: @entity4


abstract: UNASSIGNED: @entity5 ( @entity7 ) is an addictive drug that can cause @entity1 and @entity0 . Several pieces of evidence have demonstrated that @entity7 @entity1 results in increases in oxidative stress that regulate an intracellular signaling cascade that leads to cell death. Recently, several studies have emphasized that the overload of cytosolic @entity2 levels and mitochondrial fission into a small mitochondrial structure is involved in cell death processes. In the present study, we aimed to investigate the effects of @entity7 @entity1 on cytosolic @entity2 overload and mitochondrial fission in @entity3 SH-SY5Y cells. Additionally, the protective effect of @entity6 against @entity7 -induced @entity1 was also investigated. The results of the present study demonstrated that @entity7 significantly decreases cell viability and increases the levels of mitochondrial fission ( @entity9 and @entity8 ) proteins and pro-apoptotic protein, @entity4 in isolated mitochondria. The levels of @entity8 in the cytosol of @entity7 -treated cells had no significant differences compared to the control untreated cells. @entity7 also significantly increased the cytosolic @entity2 levels. @entity6 reversed the toxic effects of @entity7 by restoring cell viability and inhibiting the increase in mitochondrial @entity9 levels and the mitochondrial translocation of @entity8 and @entity4 . Additionally, @entity6 was able to reduce the @entity7 -induced increase in cytosolic @entity2 levels and fragmented mitochondria into small globular structures in SH-SY5Y cells. The results of the present study demonstrate the potential abilities of @entity6 to maintain the homeostasis of mitochondrial dynamics and cytosolic @entity2 levels in @entity7 -induced @entity1 in neuronal cells.

title: @entity6 attenuates the mitochondrial translocation of mitochondrial fission proteins and @entity4 , cytosolic @entity2 overload and cell death in @entity5 -induced @entity1 in XXXX SH-SY5Y cells.

answer: @entity3


abstract: UNASSIGNED: @entity5 ( @entity7 ) is an addictive drug that can cause @entity1 and @entity0 . Several pieces of evidence have demonstrated that @entity7 @entity1 results in increases in oxidative stress that regulate an intracellular signaling cascade that leads to cell death. Recently, several studies have emphasized that the overload of cytosolic @entity2 levels and mitochondrial fission into a small mitochondrial structure is involved in cell death processes. In the present study, we aimed to investigate the effects of @entity7 @entity1 on cytosolic @entity2 overload and mitochondrial fission in @entity3 SH-SY5Y cells. Additionally, the protective effect of @entity6 against @entity7 -induced @entity1 was also investigated. The results of the present study demonstrated that @entity7 significantly decreases cell viability and increases the levels of mitochondrial fission ( @entity9 and @entity8 ) proteins and pro-apoptotic protein, @entity4 in isolated mitochondria. The levels of @entity8 in the cytosol of @entity7 -treated cells had no significant differences compared to the control untreated cells. @entity7 also significantly increased the cytosolic @entity2 levels. @entity6 reversed the toxic effects of @entity7 by restoring cell viability and inhibiting the increase in mitochondrial @entity9 levels and the mitochondrial translocation of @entity8 and @entity4 . Additionally, @entity6 was able to reduce the @entity7 -induced increase in cytosolic @entity2 levels and fragmented mitochondria into small globular structures in SH-SY5Y cells. The results of the present study demonstrate the potential abilities of @entity6 to maintain the homeostasis of mitochondrial dynamics and cytosolic @entity2 levels in @entity7 -induced @entity1 in neuronal cells.

title: @entity6 attenuates the mitochondrial translocation of mitochondrial fission proteins and @entity4 , cytosolic XXXX overload and cell death in @entity5 -induced @entity1 in @entity3 SH-SY5Y cells.

answer: @entity2


abstract: Abstract 1. @entity4 ( @entity3 ) is a new type of triazolinthione fungicide used worldwide. Despite its widespread use, the basic toxicokinetics (TK) information for health risk assessments of @entity3 is limited. 2. TK behavior and metabolism studies of @entity3 were performed in male adult Sprague Dawley (SD) @entity0 after a single oral administration. Serial blood and tissue samples were analyzed for their @entity3 content by high-performance liquid chromatography (HPLC) to obtain comprehensive time-course data for estimation of TK parameters. 3. @entity3 was rapidly but incompletely absorbed from the gastrointestinal tract of fasted adult @entity0 . It was widely distributed in all parts of body, but demonstrated little tendency to accumulate. And @entity3 was excreted mainly in the form of parent compound. 4. The detection of @entity3 in brain and testis proved that further investigations are required to determine whether @entity3 could result in @entity2 and @entity1 .

title: Toxicokinetics and tissue distribution of XXXX in male adult @entity0 following a single oral administration.

answer: @entity4


abstract: Abstract 1. @entity4 ( @entity3 ) is a new type of triazolinthione fungicide used worldwide. Despite its widespread use, the basic toxicokinetics (TK) information for health risk assessments of @entity3 is limited. 2. TK behavior and metabolism studies of @entity3 were performed in male adult Sprague Dawley (SD) @entity0 after a single oral administration. Serial blood and tissue samples were analyzed for their @entity3 content by high-performance liquid chromatography (HPLC) to obtain comprehensive time-course data for estimation of TK parameters. 3. @entity3 was rapidly but incompletely absorbed from the gastrointestinal tract of fasted adult @entity0 . It was widely distributed in all parts of body, but demonstrated little tendency to accumulate. And @entity3 was excreted mainly in the form of parent compound. 4. The detection of @entity3 in brain and testis proved that further investigations are required to determine whether @entity3 could result in @entity2 and @entity1 .

title: Toxicokinetics and tissue distribution of @entity4 in male adult XXXX following a single oral administration.

answer: @entity0


abstract: BACKGROUND: In @entity0 with @entity1 ( @entity1 ) on infliximab, data are limited on immune response to @entity2 vaccine and the impact of vaccine timing. The study aims were to evaluate immune responses to the @entity2 vaccine in @entity1 @entity0 on infliximab and the impact of vaccine timing on immune responses. METHODS: In this randomized study, 137 subjects with @entity1 on maintenance infliximab therapy were allocated to receive the 2012/2013 inactivated @entity2 vaccine at the time of infliximab infusion (n = 69) or midway between infusions (n = 68). Serum was collected before and after vaccination for hemagglutination inhibition titers. Serologic protection was defined by postvaccine titer of >= 1:40. RESULTS: Comparing subjects vaccinated at the time of infliximab with those vaccinated midway, serologic protection was achieved in 67% versus 66% to H1N1 (P = 0.8), in 43% versus 49% to H3N2 (P = 0.5), and in 69% versus 79% to @entity2 B (P = 0.2). Although solicited adverse events were common (60%), no subject experienced a serious adverse event requiring additional medical attention. Only 6% of subjects had a clinically significant increase in disease activity score, not impacted by vaccine timing. CONCLUSIONS: Serologic protection to @entity2 vaccine is achieved in only approximately 45% to 80% of @entity1 @entity0 on maintenance infliximab therapy varying by antigen. Yet, importantly, vaccine timing relative to infliximab infusion does not affect the achievement of serologic protection, and the @entity2 vaccine is well tolerated. Therefore, @entity2 vaccination at any point during infliximab scheduling is recommended for @entity0 with @entity1 and opportunities to broaden the availability and convenience of @entity2 vaccine to optimize coverage should be explored.

title: Immunogenicity of Influenza Vaccine for @entity0 with XXXX on Maintenance Infliximab Therapy: A Randomized Trial.

answer: @entity1


abstract: BACKGROUND: In @entity0 with @entity1 ( @entity1 ) on infliximab, data are limited on immune response to @entity2 vaccine and the impact of vaccine timing. The study aims were to evaluate immune responses to the @entity2 vaccine in @entity1 @entity0 on infliximab and the impact of vaccine timing on immune responses. METHODS: In this randomized study, 137 subjects with @entity1 on maintenance infliximab therapy were allocated to receive the 2012/2013 inactivated @entity2 vaccine at the time of infliximab infusion (n = 69) or midway between infusions (n = 68). Serum was collected before and after vaccination for hemagglutination inhibition titers. Serologic protection was defined by postvaccine titer of >= 1:40. RESULTS: Comparing subjects vaccinated at the time of infliximab with those vaccinated midway, serologic protection was achieved in 67% versus 66% to H1N1 (P = 0.8), in 43% versus 49% to H3N2 (P = 0.5), and in 69% versus 79% to @entity2 B (P = 0.2). Although solicited adverse events were common (60%), no subject experienced a serious adverse event requiring additional medical attention. Only 6% of subjects had a clinically significant increase in disease activity score, not impacted by vaccine timing. CONCLUSIONS: Serologic protection to @entity2 vaccine is achieved in only approximately 45% to 80% of @entity1 @entity0 on maintenance infliximab therapy varying by antigen. Yet, importantly, vaccine timing relative to infliximab infusion does not affect the achievement of serologic protection, and the @entity2 vaccine is well tolerated. Therefore, @entity2 vaccination at any point during infliximab scheduling is recommended for @entity0 with @entity1 and opportunities to broaden the availability and convenience of @entity2 vaccine to optimize coverage should be explored.

title: Immunogenicity of Influenza Vaccine for XXXX with @entity1 on Maintenance Infliximab Therapy: A Randomized Trial.

answer: @entity0


abstract: PURPOSE: To evaluate the outcomes of @entity1 rehabilitation (LVR) in adults with @entity1 ( @entity1 ) in India using the Veterans Affairs Low Vision Visual Functioning Questionnaire (VA @entity1 VFQ-48) and the Impact of Vision Impairment (IVI) questionnaire. METHODS: Consecutive adults with @entity1 referred for the first time to the Centre for Sight Enhancement were administered the 28-item IVI and VA @entity1 VFQ-48 before and after LVR (4 months). Rasch-scaled scores were generated for the IVI and the VA @entity1 VFQ-48 along with each of their subscales at both the time points. @entity2 ( @entity2 ) was calculated using Cohen's d coefficient. RESULTS: Two hundred fifty-five @entity0 completed the LVR program. Following LVR, the linear measures revealed significant improvements in vision-related quality of life (VRQoL) using the IVI at follow-up (P < 0.0001), with large @entity2 for reading and accessing information ( @entity2 = 1.0) and relatively moderate @entity2 for overall IVI ( @entity2 = 0.63) and mobility subscale ( @entity2 = 0.53). No significant improvement was found on emotional well-being subscale ( @entity2 = 0.18; P = 0.06). Similarly, significant improvements in VRQoL (P < 0.0001) were found for the VA @entity1 VFQ-48 at follow-up, albeit moderate @entity2 for the overall visual ability ( @entity2 = -0.67) and its subscales (reading [ @entity2 = -0.72], mobility [ @entity2 = -0.45], visual information [ @entity2 = -0.47), visual motor [ @entity2 = -0.54]). CONCLUSIONS: Regardless of the instrument used for assessment, our multidisciplinary LVR program resulted in statistically significant improvements in visual functioning and VRQoL of those adults with @entity1 deemed appropriate for intervention (dropout rates were high); however, the improvements were modest, and the clinical relevance of these small improvements may be limited. Nonetheless, further studies should attempt to increase the completion rates in order to draw strong inferences.

title: Outcomes of XXXX Rehabilitation in Adults.

answer: @entity1


abstract: Issue addressed @entity2 ( @entity2 ) is a lifestyle modification program that promotes healthy diet, physical activity and stress management techniques. Among US @entity2 @entity0 , differences in gender responsiveness to improvements in chronic disease risk factors were demonstrated. This study examined gender differences in outcomes to the @entity2 intervention in Australasia. Methods Changes in body weight, blood pressure (BP), blood lipid profile and fasting plasma @entity3 (FPG) were assessed in 925 @entity0 (34.3% @entity0 , mean age=56.0  12.5 years; 65.7% @entity0 , mean age=54.4  13.5 years) 30 days after program commencement. Results Significant reductions (P<0.001) in all biometrics measured were found for @entity0 and @entity0 but were greater among @entity0 for total (TC) and low-density lipoprotein @entity1 (LDL), @entity4 (TG), FPG, body mass index (BMI) and TC/high-density lipoprotein @entity1 (HDL) ratio. @entity0 with highest baseline classifications of BMI, systolic BP, blood lipids and FPG showed greatest reductions in 30 days. Conclusions @entity2 more effectively reduced chronic disease risk factors among @entity0 than @entity0 . All @entity0 , but particularly @entity0 , entering the program with the greatest risk achieved the largest reductions. Possible physiological or behavioural factors include food preferences, making commitments and differential support modes. So what? Developers of lifestyle intervention programs should consider gender differences in physiological and behavioural factors when planning interventions. In particular, developers should manage expectations of @entity0 entering lifestyle interventions to increase awareness that @entity0 tend to respond better than @entity0 . In addition, this is a call for further research to identify the underlying mechanisms responsible for the disproportionate responsiveness of males.

title: Gender differences in effectiveness of the @entity2 ( XXXX ) lifestyle intervention: an Australasian study.

answer: @entity2


abstract: Issue addressed @entity2 ( @entity2 ) is a lifestyle modification program that promotes healthy diet, physical activity and stress management techniques. Among US @entity2 @entity0 , differences in gender responsiveness to improvements in chronic disease risk factors were demonstrated. This study examined gender differences in outcomes to the @entity2 intervention in Australasia. Methods Changes in body weight, blood pressure (BP), blood lipid profile and fasting plasma @entity3 (FPG) were assessed in 925 @entity0 (34.3% @entity0 , mean age=56.0  12.5 years; 65.7% @entity0 , mean age=54.4  13.5 years) 30 days after program commencement. Results Significant reductions (P<0.001) in all biometrics measured were found for @entity0 and @entity0 but were greater among @entity0 for total (TC) and low-density lipoprotein @entity1 (LDL), @entity4 (TG), FPG, body mass index (BMI) and TC/high-density lipoprotein @entity1 (HDL) ratio. @entity0 with highest baseline classifications of BMI, systolic BP, blood lipids and FPG showed greatest reductions in 30 days. Conclusions @entity2 more effectively reduced chronic disease risk factors among @entity0 than @entity0 . All @entity0 , but particularly @entity0 , entering the program with the greatest risk achieved the largest reductions. Possible physiological or behavioural factors include food preferences, making commitments and differential support modes. So what? Developers of lifestyle intervention programs should consider gender differences in physiological and behavioural factors when planning interventions. In particular, developers should manage expectations of @entity0 entering lifestyle interventions to increase awareness that @entity0 tend to respond better than @entity0 . In addition, this is a call for further research to identify the underlying mechanisms responsible for the disproportionate responsiveness of males.

title: Gender differences in effectiveness of the XXXX ( @entity2 ) lifestyle intervention: an Australasian study.

answer: @entity2


abstract: In @entity1 ( @entity1 ), persistent (allo)immune-mediated inflammation eventually leads to tissue remodeling including @entity5 formation in intragraft arteries. We previously showed that recipient-derived neointimal @entity2 (+) smooth muscle-like cells are present in @entity0 renal allografts with @entity1 . @entity0 PBMC contain myeloid cells capable of differentiating into @entity2 (+) cells in vitro; the phenotype of the ancestral subset is as yet unknown. This study aimed to investigate whether monocyte subsets contain cells with smooth muscle-like cell differentiation capacity and whether @entity1 in renal transplant recipients is associated with a shift in these monocyte subsets. To accomplish this goal, monocyte subsets from healthy controls were sorted based on @entity4 and @entity3 expression to investigate gene expression levels of mesenchymal markers @entity2 and @entity6 . @entity4 (+)/ @entity3 (++) monocytes displayed increased @entity2 and @entity6 mRNA expression compared with @entity4 (++)/ @entity3 (-) monocytes, suggesting increased differentiation potential toward smooth muscle-like cells. Flow cytometry revealed that in non- @entity1 transplant recipients the percentage of @entity4 (+)/ @entity3 (++) monocytes was reduced, with an even further reduction in @entity0 with @entity1 . To determine a potential correlation between @entity4 (+)/ @entity3 (++) monocytes and @entity2 (+) cell outgrowth potential in vitro, PBMC of healthy controls and transplant recipients with and without @entity1 were cultured under fibrotic culture conditions, and indeed a significant correlation (p=0.0002, r=0.62) was observed. Finally, double staining for @entity2 and @entity3 revealed presence of @entity2 (+) @entity3 (+) cells in kidney explants from @entity1 @entity0 , albeit at very low numbers. Our data represent evidence that, compared to @entity4 (++) @entity3 (-) monocytes, @entity4 (+) @entity3 (++) monocytes have an increased expression of smooth muscle cell-associated genes. This monocyte subpopulation is reduced in renal transplant @entity0 with @entity1 , possibly due to selective migration into the allograft.

title: XXXX (+) monocytes with smooth muscle cell characteristics are reduced in @entity0 renal chronic transplant dysfunction.

answer: @entity3


abstract: In @entity1 ( @entity1 ), persistent (allo)immune-mediated inflammation eventually leads to tissue remodeling including @entity5 formation in intragraft arteries. We previously showed that recipient-derived neointimal @entity2 (+) smooth muscle-like cells are present in @entity0 renal allografts with @entity1 . @entity0 PBMC contain myeloid cells capable of differentiating into @entity2 (+) cells in vitro; the phenotype of the ancestral subset is as yet unknown. This study aimed to investigate whether monocyte subsets contain cells with smooth muscle-like cell differentiation capacity and whether @entity1 in renal transplant recipients is associated with a shift in these monocyte subsets. To accomplish this goal, monocyte subsets from healthy controls were sorted based on @entity4 and @entity3 expression to investigate gene expression levels of mesenchymal markers @entity2 and @entity6 . @entity4 (+)/ @entity3 (++) monocytes displayed increased @entity2 and @entity6 mRNA expression compared with @entity4 (++)/ @entity3 (-) monocytes, suggesting increased differentiation potential toward smooth muscle-like cells. Flow cytometry revealed that in non- @entity1 transplant recipients the percentage of @entity4 (+)/ @entity3 (++) monocytes was reduced, with an even further reduction in @entity0 with @entity1 . To determine a potential correlation between @entity4 (+)/ @entity3 (++) monocytes and @entity2 (+) cell outgrowth potential in vitro, PBMC of healthy controls and transplant recipients with and without @entity1 were cultured under fibrotic culture conditions, and indeed a significant correlation (p=0.0002, r=0.62) was observed. Finally, double staining for @entity2 and @entity3 revealed presence of @entity2 (+) @entity3 (+) cells in kidney explants from @entity1 @entity0 , albeit at very low numbers. Our data represent evidence that, compared to @entity4 (++) @entity3 (-) monocytes, @entity4 (+) @entity3 (++) monocytes have an increased expression of smooth muscle cell-associated genes. This monocyte subpopulation is reduced in renal transplant @entity0 with @entity1 , possibly due to selective migration into the allograft.

title: @entity3 (+) monocytes with smooth muscle cell characteristics are reduced in XXXX renal chronic transplant dysfunction.

answer: @entity0


abstract: AIMS: To assess the efficacy and safety of @entity2 and @entity1 ( @entity7 )-based immunosuppressive regimens in Chinese de novo kidney transplant recipients who are @entity3 expressers. METHODS: The @entity3 ( @entity4 , @entity5 ) polymorphism of eligible @entity0 was determined before transplantation. De novo kidney transplant recipients enrolled in this study were assigned to @entity2 (Tac group) or @entity7 ( @entity7 group) based therapy. The follow-up period was 2  years. The incidence of acute rejection, @entity0 and graft survival rates, renal allograft function and post-transplant complications were compared. The intra-individual variability (IIV) of Tac and @entity7 blood concentrations was analysed. Medication costs were also compared. The analysis was conducted on the intention-to-treat principle. RESULTS: A total of 72 @entity3 expressers were enrolled, with 36 @entity0 in each group. AR incidence was higher in the Tac group (11.1% vs. 5.6%), but there was no significant difference (p  >  0.05). The 2-year @entity0 and graft survival was comparable, and renal function was comparable in the two groups. Notably, the Tac group presented a significantly higher incidence of BK viremia (22.2% vs. 5.6%, p  <  0.05) and BK viruria (38.9% vs. 16.7%, p  <  0.05) than the @entity7 group. The @entity7 IIV at 1 and 3  months post-transplant was significantly lower than the Tac IIV (p  <  0.05). The medical costs of both immunosuppressive drugs and management of complications was significantly lower in the @entity7 group. CONCLUSIONS: @entity1 -based maintenance therapy is safe for Chinese de novo kidney transplant recipients who are @entity3 expressers. @entity7 significantly reduced medication costs and decreased @entity6 infection, suggesting that it is more beneficial for this specific population.

title: Comparison of @entity2 and XXXX in @entity3 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.

answer: @entity1


abstract: AIMS: To assess the efficacy and safety of @entity2 and @entity1 ( @entity7 )-based immunosuppressive regimens in Chinese de novo kidney transplant recipients who are @entity3 expressers. METHODS: The @entity3 ( @entity4 , @entity5 ) polymorphism of eligible @entity0 was determined before transplantation. De novo kidney transplant recipients enrolled in this study were assigned to @entity2 (Tac group) or @entity7 ( @entity7 group) based therapy. The follow-up period was 2  years. The incidence of acute rejection, @entity0 and graft survival rates, renal allograft function and post-transplant complications were compared. The intra-individual variability (IIV) of Tac and @entity7 blood concentrations was analysed. Medication costs were also compared. The analysis was conducted on the intention-to-treat principle. RESULTS: A total of 72 @entity3 expressers were enrolled, with 36 @entity0 in each group. AR incidence was higher in the Tac group (11.1% vs. 5.6%), but there was no significant difference (p  >  0.05). The 2-year @entity0 and graft survival was comparable, and renal function was comparable in the two groups. Notably, the Tac group presented a significantly higher incidence of BK viremia (22.2% vs. 5.6%, p  <  0.05) and BK viruria (38.9% vs. 16.7%, p  <  0.05) than the @entity7 group. The @entity7 IIV at 1 and 3  months post-transplant was significantly lower than the Tac IIV (p  <  0.05). The medical costs of both immunosuppressive drugs and management of complications was significantly lower in the @entity7 group. CONCLUSIONS: @entity1 -based maintenance therapy is safe for Chinese de novo kidney transplant recipients who are @entity3 expressers. @entity7 significantly reduced medication costs and decreased @entity6 infection, suggesting that it is more beneficial for this specific population.

title: Comparison of @entity2 and @entity1 in XXXX expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.

answer: @entity3


abstract: AIMS: To assess the efficacy and safety of @entity2 and @entity1 ( @entity7 )-based immunosuppressive regimens in Chinese de novo kidney transplant recipients who are @entity3 expressers. METHODS: The @entity3 ( @entity4 , @entity5 ) polymorphism of eligible @entity0 was determined before transplantation. De novo kidney transplant recipients enrolled in this study were assigned to @entity2 (Tac group) or @entity7 ( @entity7 group) based therapy. The follow-up period was 2  years. The incidence of acute rejection, @entity0 and graft survival rates, renal allograft function and post-transplant complications were compared. The intra-individual variability (IIV) of Tac and @entity7 blood concentrations was analysed. Medication costs were also compared. The analysis was conducted on the intention-to-treat principle. RESULTS: A total of 72 @entity3 expressers were enrolled, with 36 @entity0 in each group. AR incidence was higher in the Tac group (11.1% vs. 5.6%), but there was no significant difference (p  >  0.05). The 2-year @entity0 and graft survival was comparable, and renal function was comparable in the two groups. Notably, the Tac group presented a significantly higher incidence of BK viremia (22.2% vs. 5.6%, p  <  0.05) and BK viruria (38.9% vs. 16.7%, p  <  0.05) than the @entity7 group. The @entity7 IIV at 1 and 3  months post-transplant was significantly lower than the Tac IIV (p  <  0.05). The medical costs of both immunosuppressive drugs and management of complications was significantly lower in the @entity7 group. CONCLUSIONS: @entity1 -based maintenance therapy is safe for Chinese de novo kidney transplant recipients who are @entity3 expressers. @entity7 significantly reduced medication costs and decreased @entity6 infection, suggesting that it is more beneficial for this specific population.

title: Comparison of XXXX and @entity1 in @entity3 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.

answer: @entity2


abstract: @entity0 intracellulare strain LR25 carries three plasmids with molecular weights of 11.2, 18.3 and 107 X 10(6) as determined by electron microscopy. A number of phages propagated on @entity1 ATCC 607 were tested for their ability to infect strain LR25. Phage JF2 gave an efficiency of plating of 10(-4) on strain LR25, but phage JF2 propagated on strain LR25 infected strain LR25 and @entity1 with equal high efficiency. This indicated the presence of a restriction-modification (R-M) system in strain LR25 that was not present in @entity1 LR25 was grown in the presence of @entity2 to eliminate the plasmids and tested for sensitivity to phage JF2. One of forty colonies was found to be R-M-deficient. This strain, designated strain LR163, lacks the three plasmids present in strain LR25. The results indicate that the R-M system is plasmid-coded. Strain LR163 was sensitive to several phages to which strain LR25 was resistant and for which we were unable to isolate modified phage. This suggests that some plasmid-coded function in addition to restriction is involved. An R-M system was also demonstrated in @entity0 intracellulare strain LR131 using phage JF1. This strain does not carry plasmids.

title: Evidence for plasmid-mediated restriction-modification in XXXX intracellulare.

answer: @entity0


abstract: In recent years, @entity9 has increasingly been used in pollution monitoring studies. In order to assess its response to some particular widespread pollutants, juveniles of @entity9 were administered an intraperitoneal injection of the model aryl hydrocarbon receptor agonist b-naphtoflavone (bNF) and chemicals of environmental concern, such as the fungicide @entity5 (KETO), the lipid regulator @entity8 (GEM), the surfactant @entity3 (NP) and the synthetic hormone @entity4 ( @entity7 ). Two days after injection, the effect of these chemicals was followed up as alterations of hepatic microsomal activities of the cytochrome P450 (CYPs) and associated reductases, carboxylesterases (CbEs) and the conjugation enzyme @entity2 glucuronyltransferase (UDPGT). In the cytosolic fraction of the liver, the effect on CbEs, glutathione S-transferase (GST) and antioxidant activities was also considered. Alterations on the endocrine reproductive system were evaluated by plasma levels of vitellogenin (VTG) and the sex steroids estradiol (E2), @entity1 (T), @entity6 (11KT) and the progestin 17a,20b-dihydroxy-4-pregnen-3-one (17,20b-P). Injection with the model compound bNF induced the hydrolysis rate of the seven CYP substrates assayed. The xenobiotic GEM induced three CYP-related activities (e.g. ECOD) and UDPGT, but depressed antioxidant defenses. @entity7 induced four CYPs, more significantly ECOD and BFCOD activities. The xenoestrogens NP and @entity7 altered the activities of CbE in microsomes and catalase, and were the only treatments that induced de novo VTG synthesis. In addition, the progestin 17,20b-P, was induced in NP-injected fish. None of the treatments caused statistically significant effects on @entity0 plasma levels. In conclusion, the CYP substrates assayed responded specifically to treatments and juveniles of @entity9 appear good candidates for assessing xenobiotics exposure.

title: Effects of selected xenobiotics on hepatic and plasmatic biomarkers in juveniles of XXXX .

answer: @entity9


abstract: UNASSIGNED: We tested if serum lipid and lipoprotein @entity2 levels are associated with longitudinal measures of @entity1 ( @entity1 ) in 1289 African ancestry @entity0 . After 6  years of mean follow-up, @entity0 with clinically optimal levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), or @entity5 at baseline experienced the greatest @entity1 loss, independent of potential confounding factors (all p   <   0.05). INTRODUCTION: Studies of lipid and lipoprotein @entity2 associations with @entity1 ( @entity1 ) and @entity4 have been inconclusive, and longitudinal data are sparse. Therefore, the aim of this study was to test if fasting serum lipid and lipoprotein @entity2 levels are associated with areal and volumetric @entity1 and @entity1 change. METHODS: We determined the association of serum @entity5 , high-density lipoprotein (HDL), and low-density lipoprotein (LDL) @entity2 concentrations with cross-sectional and longitudinal (mean follow-up, 6.1  years) measures of @entity1 in a cohort of 1289 in African ancestry @entity0 (mean age, 56.4  years). Fasting serum @entity5 , HDL, and LDL were measured at baseline concurrent with @entity1 assessments. Dual-energy X-ray absorptiometry was used to quantify integral hip @entity1 , and peripheral quantitative computed tomography at the radius and tibia was used to quantify volumetric @entity1 . @entity0 were categorized as optimal, borderline, or high risk for @entity3 , HDL, and LDL concentrations based on Adult Treatment Panel III guidelines. RESULTS: Lower serum @entity3 or LDL and higher HDL concentrations were associated with lower trabecular @entity1 at baseline (all p   <   0.05). Similarly, @entity0 classified as having optimal levels of LDL, HDL, or @entity5 at baseline experienced the greatest integral @entity1 loss at the hip and trabecular @entity1 loss at the tibia (all p   <   0.05), independent of potential confounding factors. CONCLUSIONS: We found that clinically optimal serum lipid and lipoprotein @entity2 concentrations were associated with accelerated @entity4 among Afro-Caribbean @entity0 . Further studies are needed to better understand the mechanisms involved and potential clinical significance of these findings.

title: Optimal serum @entity2 concentrations are associated with accelerated XXXX in African ancestry @entity0 .

answer: @entity4


abstract: UNASSIGNED: We tested if serum lipid and lipoprotein @entity2 levels are associated with longitudinal measures of @entity1 ( @entity1 ) in 1289 African ancestry @entity0 . After 6  years of mean follow-up, @entity0 with clinically optimal levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), or @entity5 at baseline experienced the greatest @entity1 loss, independent of potential confounding factors (all p   <   0.05). INTRODUCTION: Studies of lipid and lipoprotein @entity2 associations with @entity1 ( @entity1 ) and @entity4 have been inconclusive, and longitudinal data are sparse. Therefore, the aim of this study was to test if fasting serum lipid and lipoprotein @entity2 levels are associated with areal and volumetric @entity1 and @entity1 change. METHODS: We determined the association of serum @entity5 , high-density lipoprotein (HDL), and low-density lipoprotein (LDL) @entity2 concentrations with cross-sectional and longitudinal (mean follow-up, 6.1  years) measures of @entity1 in a cohort of 1289 in African ancestry @entity0 (mean age, 56.4  years). Fasting serum @entity5 , HDL, and LDL were measured at baseline concurrent with @entity1 assessments. Dual-energy X-ray absorptiometry was used to quantify integral hip @entity1 , and peripheral quantitative computed tomography at the radius and tibia was used to quantify volumetric @entity1 . @entity0 were categorized as optimal, borderline, or high risk for @entity3 , HDL, and LDL concentrations based on Adult Treatment Panel III guidelines. RESULTS: Lower serum @entity3 or LDL and higher HDL concentrations were associated with lower trabecular @entity1 at baseline (all p   <   0.05). Similarly, @entity0 classified as having optimal levels of LDL, HDL, or @entity5 at baseline experienced the greatest integral @entity1 loss at the hip and trabecular @entity1 loss at the tibia (all p   <   0.05), independent of potential confounding factors. CONCLUSIONS: We found that clinically optimal serum lipid and lipoprotein @entity2 concentrations were associated with accelerated @entity4 among Afro-Caribbean @entity0 . Further studies are needed to better understand the mechanisms involved and potential clinical significance of these findings.

title: Optimal serum XXXX concentrations are associated with accelerated @entity4 in African ancestry @entity0 .

answer: @entity2


abstract: UNASSIGNED: We tested if serum lipid and lipoprotein @entity2 levels are associated with longitudinal measures of @entity1 ( @entity1 ) in 1289 African ancestry @entity0 . After 6  years of mean follow-up, @entity0 with clinically optimal levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), or @entity5 at baseline experienced the greatest @entity1 loss, independent of potential confounding factors (all p   <   0.05). INTRODUCTION: Studies of lipid and lipoprotein @entity2 associations with @entity1 ( @entity1 ) and @entity4 have been inconclusive, and longitudinal data are sparse. Therefore, the aim of this study was to test if fasting serum lipid and lipoprotein @entity2 levels are associated with areal and volumetric @entity1 and @entity1 change. METHODS: We determined the association of serum @entity5 , high-density lipoprotein (HDL), and low-density lipoprotein (LDL) @entity2 concentrations with cross-sectional and longitudinal (mean follow-up, 6.1  years) measures of @entity1 in a cohort of 1289 in African ancestry @entity0 (mean age, 56.4  years). Fasting serum @entity5 , HDL, and LDL were measured at baseline concurrent with @entity1 assessments. Dual-energy X-ray absorptiometry was used to quantify integral hip @entity1 , and peripheral quantitative computed tomography at the radius and tibia was used to quantify volumetric @entity1 . @entity0 were categorized as optimal, borderline, or high risk for @entity3 , HDL, and LDL concentrations based on Adult Treatment Panel III guidelines. RESULTS: Lower serum @entity3 or LDL and higher HDL concentrations were associated with lower trabecular @entity1 at baseline (all p   <   0.05). Similarly, @entity0 classified as having optimal levels of LDL, HDL, or @entity5 at baseline experienced the greatest integral @entity1 loss at the hip and trabecular @entity1 loss at the tibia (all p   <   0.05), independent of potential confounding factors. CONCLUSIONS: We found that clinically optimal serum lipid and lipoprotein @entity2 concentrations were associated with accelerated @entity4 among Afro-Caribbean @entity0 . Further studies are needed to better understand the mechanisms involved and potential clinical significance of these findings.

title: Optimal serum @entity2 concentrations are associated with accelerated @entity4 in African ancestry XXXX .

answer: @entity0


abstract: The authors have developed a kinetic dye test protocol that aims to predict the competitive adsorption of @entity7 ( @entity2 ) to granular activated carbons (GACs). The kinetic dye test takes about two hours to perform, and produces a quantitative result, fitted to a model to yield an @entity4 ( @entity4 ) during the earlier times of dye sorption. The dye @entity6 orange was probed into six coconut-based GACs and five bituminous-based GACs that hosted varied pore distributions. Correlations between @entity6 orange IDCs and breakthrough of @entity2 at 4  ppt in rapid small-scale column tests (RSSCTs) were found with R(2)s of 0.85 and 0.95 for coconut carbons that processed waters with total organic @entity0 (TOCs) of 1.9 and 2.2  ppm, respectively, and with an R(2) of 0.94 for bituminous carbons that processed waters with a TOC of 2.5  ppm. The author sought to study the influence of the pore sizes, which provide the adsorption sites and the diffusion conduits that are necessary for the removal of those compounds. For coconut carbons, a linear correlation was established between the @entity6 orange IDCs and the volume of pores in the range of 23.4-31.8     widths (R(2)  =  0.98). For bituminous carbons, best correlation was to pores ranging from 74 to 93     widths (R(2)  =  0.94). The differences in adsorption between coconut carbons and bituminous carbons have been attributed to the inherently dissimilar @entity5 layering resulting from the parent materials and the activation processes. When @entity1 dye was employed in the kinetic dye tests, the correlations to @entity2 performance were not as high as when @entity6 orange was used. Intriguingly, it was the same pore size ranges that exhibited the strongest correlation for @entity2 RSSCT's, @entity6 orange kinetics, and fluoroscein kinetics. When @entity3 dye was used, sorption occurred so rapidly as to be out of the scope of the @entity4 model.

title: A rapid kinetic dye test to predict the adsorption of XXXX onto granular activated carbons and to identify the influence of pore volume distributions.

answer: @entity7


abstract: AIMS: The @entity8 /ROCK pathway controls crucial biological processes involved in cardiovascular pathophysiology, such as cytoskeleton dynamics, vascular smooth muscle contraction, and @entity2 . In this work, we tested whether Rho kinase inhibition would beneficially impact cardiac cytoskeleton organization, bioenergetics, and autophagy in experimental @entity9 induced by lipopolysaccharides (LPSs) in @entity1 . RESULTS: @entity10 , a potent ROCK inhibitor, prevented @entity6 -induced @entity5 , oxidative stress, cytoskeleton disarray, and @entity7 . ROCK inhibition prevented phosphorylation of @entity11 and @entity12 , which promotes stabilization-polymerization of F-actin and mediates mitochondrial fission, respectively. Pyr1, which exclusively alters actin dynamics, prevented @entity6 -induced @entity4 , suggesting that beneficial impact of ROCK inhibition was not mainly related to pleiotropic effects of @entity10 on @entity5 and oxidative stress. @entity10 reduced mitochondrial fragmentation, stimulated initiation of autophagy, and elicited cardioprotection in @entity6 heart. Mdivi-1, a potent mitochondria fission inhibitor, converted cardioprotective autophagy to an inefficient form due to cargo loading failure in which autophagic vacuoles fail to trap cytosolic cargo, despite their formation at enhanced rates and lysosomal elimination. INNOVATION: In experimental @entity9 , cardioprotection by @entity8 /ROCK inhibition may be related to changes in actin cytoskeleton reorganization and mitochondrial homeostasis. Improvement of @entity6 -induced @entity7 by @entity10 was attributed to inhibition of ROCK-dependent @entity12 phosphorylation and activation of autophagic processes that can limit mitochondrial fragmentation and enhance degradation of damaged mitochondria, respectively. CONCLUSION: @entity10 prevented @entity6 -induced heart oxidative stress, abnormal F-actin distribution, and oxidative phosphorylation, which concur to improve cardiac contractile and bioenergetic function. We suggest that @entity10 may represent a valuable therapy for @entity0 with @entity3 . Antioxid. Redox Signal. 00, 000-000.

title: Endotoxemia Engages the XXXX Kinase Pathway to Impair Cardiac Function By Altering Cytoskeleton, Mitochondrial Fission, and Autophagy.

answer: @entity8


abstract: OBJECTIVE: @entity4 is a new Xa inhibitor indicated for thromboprophylaxis in @entity0 undergoing joint arthroplasty. This study was designed to assess the risk of major @entity1 from the combination of either a single or a continuous deep, superficial, and @entity2 and the use of @entity4 for thromboprophylaxis following joint arthroplasty. METHOD: @entity0 undergoing either primary, redo, unilateral, or bilateral total hip or knee replacement while receiving a femoral, sciatic, lumbar @entity2 alone or in combination and receiving at least one dose of @entity4 10 mg once a day for thromboprophylaxis postoperatively were included in this analysis. RESULTS: In this series, 766 @entity0 (199 total hip replacements and 567 total knee replacements) were included. A total of 1,104 blocks were performed including 1,029 continuous blocks (509 femoral, 320 sciatic, and 200 lumbar plexus). No major @entity1 related to the performance of peripheral nerve blocks was recorded. In contrast, three @entity0 developed @entity3 in the operated knee requiring a surgical evacuation. @entity1 was recorded at the surgical site in 12 @entity0 vs 10 @entity0 at the site of the block. Although all minor @entity1 at the surgical site occurred after the initiation of the @entity4 therapy, 80% of minor @entity1 at the site of the block was recorded before the initiation of thromboprophylaxis. CONCLUSION: Our data supports the concept that there is no increased risk of major @entity1 when deep and superficial blocks are performed in combination in @entity0 receiving thromboprophylaxis @entity4 following joint arthroplasty.

title: Combination of Superficial and Deep Blocks with XXXX .

answer: @entity4


abstract: BACKGROUND: Venous and arterial @entity6 share a number of pathogenic mechanisms, but the burden of @entity7 ( @entity7 ) has not been consistently compared with that in other @entity4 . METHODS: We used the Spanish National Discharge Database to compare the frequency, clinical characteristics and mortality rate of all @entity0 with @entity7 , @entity8 ( @entity8 ) or @entity3 admitted from 2001 to 2010. @entity0 were classified as having primary diagnosis (the process leading to hospital admission) or secondary diagnosis (it appeared during hospital stay for other reasons) RESULTS: During the study period, 31,949,739 @entity0 were discharged. Of these, 165,229 (0.52%) were diagnosed with @entity7 , 562,837 (1.76%) with @entity8 and 495,427 (1.55%) with @entity3 . Overall, 31% of @entity0 with @entity7 , 8.4% with @entity8 and 13% with @entity3 had secondary diagnoses. The most common reasons for admission in @entity0 with secondary @entity7 were: @entity1 (21%), @entity9 (11%), @entity5 (6.4%) and @entity2 (5.5%). Mean hospital stay was: 14  13days in @entity7 @entity0 , 9.7  9.7 in those with @entity8 and 13  14days in those with @entity2 . In-hospital mortality rate was: 10.5%, 10.1% and 12.3% respectively in @entity0 with primary diagnosis, and 36%, 34% and 29% in those with secondary diagnosis. CONCLUSIONS: @entity0 hospitalized with @entity7 were 3-4 times less frequent than those with @entity8 or @entity2 , but had a higher mortality. One in every 3 @entity0 with @entity7 (but only one in every 10 with @entity8 or @entity2 ) had secondary diagnosis, and these @entity0 had the highest mortality.

title: XXXX , @entity8 and @entity3 in the Spanish National Discharge Database.

answer: @entity7


abstract: BACKGROUND: Venous and arterial @entity6 share a number of pathogenic mechanisms, but the burden of @entity7 ( @entity7 ) has not been consistently compared with that in other @entity4 . METHODS: We used the Spanish National Discharge Database to compare the frequency, clinical characteristics and mortality rate of all @entity0 with @entity7 , @entity8 ( @entity8 ) or @entity3 admitted from 2001 to 2010. @entity0 were classified as having primary diagnosis (the process leading to hospital admission) or secondary diagnosis (it appeared during hospital stay for other reasons) RESULTS: During the study period, 31,949,739 @entity0 were discharged. Of these, 165,229 (0.52%) were diagnosed with @entity7 , 562,837 (1.76%) with @entity8 and 495,427 (1.55%) with @entity3 . Overall, 31% of @entity0 with @entity7 , 8.4% with @entity8 and 13% with @entity3 had secondary diagnoses. The most common reasons for admission in @entity0 with secondary @entity7 were: @entity1 (21%), @entity9 (11%), @entity5 (6.4%) and @entity2 (5.5%). Mean hospital stay was: 14  13days in @entity7 @entity0 , 9.7  9.7 in those with @entity8 and 13  14days in those with @entity2 . In-hospital mortality rate was: 10.5%, 10.1% and 12.3% respectively in @entity0 with primary diagnosis, and 36%, 34% and 29% in those with secondary diagnosis. CONCLUSIONS: @entity0 hospitalized with @entity7 were 3-4 times less frequent than those with @entity8 or @entity2 , but had a higher mortality. One in every 3 @entity0 with @entity7 (but only one in every 10 with @entity8 or @entity2 ) had secondary diagnosis, and these @entity0 had the highest mortality.

title: @entity7 , @entity8 and XXXX in the Spanish National Discharge Database.

answer: @entity3


abstract: BACKGROUND: Venous and arterial @entity6 share a number of pathogenic mechanisms, but the burden of @entity7 ( @entity7 ) has not been consistently compared with that in other @entity4 . METHODS: We used the Spanish National Discharge Database to compare the frequency, clinical characteristics and mortality rate of all @entity0 with @entity7 , @entity8 ( @entity8 ) or @entity3 admitted from 2001 to 2010. @entity0 were classified as having primary diagnosis (the process leading to hospital admission) or secondary diagnosis (it appeared during hospital stay for other reasons) RESULTS: During the study period, 31,949,739 @entity0 were discharged. Of these, 165,229 (0.52%) were diagnosed with @entity7 , 562,837 (1.76%) with @entity8 and 495,427 (1.55%) with @entity3 . Overall, 31% of @entity0 with @entity7 , 8.4% with @entity8 and 13% with @entity3 had secondary diagnoses. The most common reasons for admission in @entity0 with secondary @entity7 were: @entity1 (21%), @entity9 (11%), @entity5 (6.4%) and @entity2 (5.5%). Mean hospital stay was: 14  13days in @entity7 @entity0 , 9.7  9.7 in those with @entity8 and 13  14days in those with @entity2 . In-hospital mortality rate was: 10.5%, 10.1% and 12.3% respectively in @entity0 with primary diagnosis, and 36%, 34% and 29% in those with secondary diagnosis. CONCLUSIONS: @entity0 hospitalized with @entity7 were 3-4 times less frequent than those with @entity8 or @entity2 , but had a higher mortality. One in every 3 @entity0 with @entity7 (but only one in every 10 with @entity8 or @entity2 ) had secondary diagnosis, and these @entity0 had the highest mortality.

title: @entity7 , XXXX and @entity3 in the Spanish National Discharge Database.

answer: @entity8


abstract: BACKGROUND: Low density lipoprotein @entity2 ( @entity8 ) is associated with @entity3 , @entity1 and increased vasoconstriction, which are involved in the development of contrast-induced @entity6 (CI-AKI). However, whether @entity8 is an independent risk factor of CI-AKI in @entity0 undergoing percutaneous coronary intervention (PCI) is unknown. METHODS: We prospectively enrolled 3236 consecutive @entity0 undergoing PCI between January 2010 and September 2012. Multivariate logistic regression analysis was used to determine whether @entity8 is an independent risk factor of CI-AKI. CI-AKI was defined as an absolute increase in serum @entity7 of >= 0.5  mg/dL or >= 25% over the baseline value within 48-72  h after contrast exposure. RESULTS: CI-AKI was observed in 338 @entity0 (10.4%). @entity0 with CI-AKI had a significantly higher rate of in hospital mortality (4.4% vs. 0.5%, p  <  0.001), and significantly higher rates of other in hospital complications compared with those without CI-AKI. The @entity8 quartiles were as follows: Q1 (<2.04  mmol/L), Q2 (2.04-2.61  mmol/L), Q3 (2.61-3.21  mmol/L) and Q4 (>3.21  mmol/L). @entity0 with high baseline @entity8 levels were more likely to develop CI-AKI and composite end points including all-cause mortality, renal replacement therapy, non-fatal @entity4 , @entity5 , target vessel revascularization or cerebrovascular accident during the observation period of hospitalization (8.9%, 9.9%, 10.5%, 12.6%, p  =  0.001, and 5.0%, 5.2%, 6.1%, 8.1%, respectively; p  =  0.007). Univariate logistic analysis showed that @entity8 levels (increment 1  mmol/L) were significantly associated with CI-AKI (odds ratio  =  1.25, 95% confidence interval (CI), 1.11-1.39, p  <  0.001). Furthermore, @entity8 remained a significant risk factor of CI-AKI (odds ratio  =  1.23, 95% CI, 1.04-1.45, p  =  0.014), even after adjusting for potential confounding risk factors. CONCLUSIONS: Measurement of plasma @entity8 concentrations in @entity0 undergoing PCI may be helpful to identify those who are at risk of CI-AKI and poor in hospital outcomes.

title: LDL @entity2 as a novel risk factor for contrast-induced XXXX in @entity0 undergoing percutaneous coronary intervention.

answer: @entity6


abstract: BACKGROUND: Low density lipoprotein @entity2 ( @entity8 ) is associated with @entity3 , @entity1 and increased vasoconstriction, which are involved in the development of contrast-induced @entity6 (CI-AKI). However, whether @entity8 is an independent risk factor of CI-AKI in @entity0 undergoing percutaneous coronary intervention (PCI) is unknown. METHODS: We prospectively enrolled 3236 consecutive @entity0 undergoing PCI between January 2010 and September 2012. Multivariate logistic regression analysis was used to determine whether @entity8 is an independent risk factor of CI-AKI. CI-AKI was defined as an absolute increase in serum @entity7 of >= 0.5  mg/dL or >= 25% over the baseline value within 48-72  h after contrast exposure. RESULTS: CI-AKI was observed in 338 @entity0 (10.4%). @entity0 with CI-AKI had a significantly higher rate of in hospital mortality (4.4% vs. 0.5%, p  <  0.001), and significantly higher rates of other in hospital complications compared with those without CI-AKI. The @entity8 quartiles were as follows: Q1 (<2.04  mmol/L), Q2 (2.04-2.61  mmol/L), Q3 (2.61-3.21  mmol/L) and Q4 (>3.21  mmol/L). @entity0 with high baseline @entity8 levels were more likely to develop CI-AKI and composite end points including all-cause mortality, renal replacement therapy, non-fatal @entity4 , @entity5 , target vessel revascularization or cerebrovascular accident during the observation period of hospitalization (8.9%, 9.9%, 10.5%, 12.6%, p  =  0.001, and 5.0%, 5.2%, 6.1%, 8.1%, respectively; p  =  0.007). Univariate logistic analysis showed that @entity8 levels (increment 1  mmol/L) were significantly associated with CI-AKI (odds ratio  =  1.25, 95% confidence interval (CI), 1.11-1.39, p  <  0.001). Furthermore, @entity8 remained a significant risk factor of CI-AKI (odds ratio  =  1.23, 95% CI, 1.04-1.45, p  =  0.014), even after adjusting for potential confounding risk factors. CONCLUSIONS: Measurement of plasma @entity8 concentrations in @entity0 undergoing PCI may be helpful to identify those who are at risk of CI-AKI and poor in hospital outcomes.

title: LDL XXXX as a novel risk factor for contrast-induced @entity6 in @entity0 undergoing percutaneous coronary intervention.

answer: @entity2


abstract: BACKGROUND: Low density lipoprotein @entity2 ( @entity8 ) is associated with @entity3 , @entity1 and increased vasoconstriction, which are involved in the development of contrast-induced @entity6 (CI-AKI). However, whether @entity8 is an independent risk factor of CI-AKI in @entity0 undergoing percutaneous coronary intervention (PCI) is unknown. METHODS: We prospectively enrolled 3236 consecutive @entity0 undergoing PCI between January 2010 and September 2012. Multivariate logistic regression analysis was used to determine whether @entity8 is an independent risk factor of CI-AKI. CI-AKI was defined as an absolute increase in serum @entity7 of >= 0.5  mg/dL or >= 25% over the baseline value within 48-72  h after contrast exposure. RESULTS: CI-AKI was observed in 338 @entity0 (10.4%). @entity0 with CI-AKI had a significantly higher rate of in hospital mortality (4.4% vs. 0.5%, p  <  0.001), and significantly higher rates of other in hospital complications compared with those without CI-AKI. The @entity8 quartiles were as follows: Q1 (<2.04  mmol/L), Q2 (2.04-2.61  mmol/L), Q3 (2.61-3.21  mmol/L) and Q4 (>3.21  mmol/L). @entity0 with high baseline @entity8 levels were more likely to develop CI-AKI and composite end points including all-cause mortality, renal replacement therapy, non-fatal @entity4 , @entity5 , target vessel revascularization or cerebrovascular accident during the observation period of hospitalization (8.9%, 9.9%, 10.5%, 12.6%, p  =  0.001, and 5.0%, 5.2%, 6.1%, 8.1%, respectively; p  =  0.007). Univariate logistic analysis showed that @entity8 levels (increment 1  mmol/L) were significantly associated with CI-AKI (odds ratio  =  1.25, 95% confidence interval (CI), 1.11-1.39, p  <  0.001). Furthermore, @entity8 remained a significant risk factor of CI-AKI (odds ratio  =  1.23, 95% CI, 1.04-1.45, p  =  0.014), even after adjusting for potential confounding risk factors. CONCLUSIONS: Measurement of plasma @entity8 concentrations in @entity0 undergoing PCI may be helpful to identify those who are at risk of CI-AKI and poor in hospital outcomes.

title: LDL @entity2 as a novel risk factor for contrast-induced @entity6 in XXXX undergoing percutaneous coronary intervention.

answer: @entity0


abstract: OBJECTIVE: Non-HDL @entity2 (non-HDL-C) has recently been recommended as a first target for @entity6 management. We previously reported that LDL @entity2 (LDL-C) and non-HDL-C levels were similarly associated with periprocedural @entity3 (PMI) following percutaneous coronary intervention (PCI) in @entity0 with @entity4 . Here we investigated the comparative prognostic value of non-HDL-C and LDL-C for PMI following PCI in @entity5 ( @entity5 ). METHODS: We prospectively enrolled 1194 consecutive @entity5 @entity0 with normal preprocedural cTnI undergoing PCI. @entity0 were divided into the two groups: group A [glycated hemoglobin (HbA1c)  <  7%, n  =  567] and group B (HbA1c  >=   7%, n  =  627). PMI was evaluated by cTnI analysis within 24  h. The relationship of preprocedural non-HDL-C and LDL-C levels with peak cTnI values after PCI was examined. RESULTS: @entity0 in group B, with higher preprocedural non-HDL-C levels, had higher postprocedural cTnI levels (b  =  0.102, P  =  0.011). In the multivariable model, a 1-SD increase in non-HDL-C produced a 30% and 33% increased risk of postprocedural cTnI >3  *  upper limit of normal (ULN) and >5  *  ULN in group B, respectively. However, neither LDL-C nor group A @entity0 were affected. Furthermore, @entity0 with non-HDL-C levels >= 130  mg/dl compared with non-HDL-C levels  <=100  mg/dl were associated with a 83.3% and 71.7% increased risk of postprocedural cTnI >3  *  ULN and >5  *  ULN in group B, respectively. CONCLUSIONS: In poorly-controlled @entity1 @entity0 (HbA1c  >=   7%) undergoing PCI, non-HDL-C but not LDL-C was independently associated with and increased risk of PMI, and non-HDL-C levels >= 130  mg/dl had a worse PMI risk profile compared with non-HDL-C levels <100  mg/dl.

title: Non-HDL @entity2 is a better target for predicting periprocedural XXXX following percutaneous coronary intervention in @entity5 .

answer: @entity3


abstract: OBJECTIVE: Non-HDL @entity2 (non-HDL-C) has recently been recommended as a first target for @entity6 management. We previously reported that LDL @entity2 (LDL-C) and non-HDL-C levels were similarly associated with periprocedural @entity3 (PMI) following percutaneous coronary intervention (PCI) in @entity0 with @entity4 . Here we investigated the comparative prognostic value of non-HDL-C and LDL-C for PMI following PCI in @entity5 ( @entity5 ). METHODS: We prospectively enrolled 1194 consecutive @entity5 @entity0 with normal preprocedural cTnI undergoing PCI. @entity0 were divided into the two groups: group A [glycated hemoglobin (HbA1c)  <  7%, n  =  567] and group B (HbA1c  >=   7%, n  =  627). PMI was evaluated by cTnI analysis within 24  h. The relationship of preprocedural non-HDL-C and LDL-C levels with peak cTnI values after PCI was examined. RESULTS: @entity0 in group B, with higher preprocedural non-HDL-C levels, had higher postprocedural cTnI levels (b  =  0.102, P  =  0.011). In the multivariable model, a 1-SD increase in non-HDL-C produced a 30% and 33% increased risk of postprocedural cTnI >3  *  upper limit of normal (ULN) and >5  *  ULN in group B, respectively. However, neither LDL-C nor group A @entity0 were affected. Furthermore, @entity0 with non-HDL-C levels >= 130  mg/dl compared with non-HDL-C levels  <=100  mg/dl were associated with a 83.3% and 71.7% increased risk of postprocedural cTnI >3  *  ULN and >5  *  ULN in group B, respectively. CONCLUSIONS: In poorly-controlled @entity1 @entity0 (HbA1c  >=   7%) undergoing PCI, non-HDL-C but not LDL-C was independently associated with and increased risk of PMI, and non-HDL-C levels >= 130  mg/dl had a worse PMI risk profile compared with non-HDL-C levels <100  mg/dl.

title: Non-HDL XXXX is a better target for predicting periprocedural @entity3 following percutaneous coronary intervention in @entity5 .

answer: @entity2


abstract: OBJECTIVE: Non-HDL @entity2 (non-HDL-C) has recently been recommended as a first target for @entity6 management. We previously reported that LDL @entity2 (LDL-C) and non-HDL-C levels were similarly associated with periprocedural @entity3 (PMI) following percutaneous coronary intervention (PCI) in @entity0 with @entity4 . Here we investigated the comparative prognostic value of non-HDL-C and LDL-C for PMI following PCI in @entity5 ( @entity5 ). METHODS: We prospectively enrolled 1194 consecutive @entity5 @entity0 with normal preprocedural cTnI undergoing PCI. @entity0 were divided into the two groups: group A [glycated hemoglobin (HbA1c)  <  7%, n  =  567] and group B (HbA1c  >=   7%, n  =  627). PMI was evaluated by cTnI analysis within 24  h. The relationship of preprocedural non-HDL-C and LDL-C levels with peak cTnI values after PCI was examined. RESULTS: @entity0 in group B, with higher preprocedural non-HDL-C levels, had higher postprocedural cTnI levels (b  =  0.102, P  =  0.011). In the multivariable model, a 1-SD increase in non-HDL-C produced a 30% and 33% increased risk of postprocedural cTnI >3  *  upper limit of normal (ULN) and >5  *  ULN in group B, respectively. However, neither LDL-C nor group A @entity0 were affected. Furthermore, @entity0 with non-HDL-C levels >= 130  mg/dl compared with non-HDL-C levels  <=100  mg/dl were associated with a 83.3% and 71.7% increased risk of postprocedural cTnI >3  *  ULN and >5  *  ULN in group B, respectively. CONCLUSIONS: In poorly-controlled @entity1 @entity0 (HbA1c  >=   7%) undergoing PCI, non-HDL-C but not LDL-C was independently associated with and increased risk of PMI, and non-HDL-C levels >= 130  mg/dl had a worse PMI risk profile compared with non-HDL-C levels <100  mg/dl.

title: Non-HDL @entity2 is a better target for predicting periprocedural @entity3 following percutaneous coronary intervention in XXXX .

answer: @entity5


abstract: OBJECTIVE: Apoptosis is the early and predominant form of cell death in infarcted myocardia. The aim of the study was to investigate the effects of @entity7 ( @entity9 ) and @entity4 (NAC), used alone or in combination, on oxidative stress, @entity5 size, and @entity2 -reperfusion (IR)-induced cardiomyocyte apoptosis in a @entity1 model of @entity3 . METHODS AND RESULTS: Myocardial IR was established by ligating an area under the left main coronary artery for 30  min followed by 3  h of reperfusion. Saline (1  ml/kg), NAC (50, 150  mg/kg), or @entity9 (3, 5  mg/kg) was intravenously injected during the middle of the @entity2 period. At the end of the reperfusion, blood samples were collected from the animals to measure serum M30 and M65 levels, which are markers of cell death, the @entity11 level, which is a marker of @entity0 , and the @entity6 ( @entity8 ) level, which is a marker of oxidative stress. The @entity5 size was evaluated as the ratio of the @entity5 area to the risk area. Apoptotic activation was assessed by @entity10 immunostaining and a TUNEL assay. @entity9 and NAC, either alone or in combination, significantly reduced serum @entity8 levels, @entity5 area and apoptotic activity compared to those observed in saline group. Interestingly, the @entity5 area was more smaller in @entity9 (3 and 5  mg/kg) injected groups (9.72      1.3% and 9.96      2.3%) than those observed in NAC (50 and 150  mg/kg) (16.1      2.5% and 19.1      2.14%) or @entity9 (5  mg/kg)- NAC (150  mg/kg) combination groups (16.9      1.6%). However, the apoptotic activity was reduced more significantly in the combination of @entity9 (5  mg/kg)-NAC (50  mg/kg) compared to @entity9 -only group. Neither @entity9 or NAC treatments nor the combination of the drugs significantly affected serum M30, M65 and @entity11 levels. CONCLUSION: Intravenous NAC and @entity9 administration decreased oxidative stress, @entity5 area and apoptotic activity in a @entity1 model of IR. Although the combination treatment was more effective in reducing the apoptotic activity than either treatment groups alone, @entity9 treatment was more successful in reducing the @entity5 area than NAC or combination treatments. Present results suggest that, in addition to mechanical attempts to secure myocardial reperfusion, the use of @entity9 and NAC may help to reduce IR injury.

title: Effective inhibition of cardiomyocyte apoptosis through the combination of @entity7 and @entity4 in a @entity1 model of XXXX and reperfusion injury.

answer: @entity3


abstract: OBJECTIVE: Apoptosis is the early and predominant form of cell death in infarcted myocardia. The aim of the study was to investigate the effects of @entity7 ( @entity9 ) and @entity4 (NAC), used alone or in combination, on oxidative stress, @entity5 size, and @entity2 -reperfusion (IR)-induced cardiomyocyte apoptosis in a @entity1 model of @entity3 . METHODS AND RESULTS: Myocardial IR was established by ligating an area under the left main coronary artery for 30  min followed by 3  h of reperfusion. Saline (1  ml/kg), NAC (50, 150  mg/kg), or @entity9 (3, 5  mg/kg) was intravenously injected during the middle of the @entity2 period. At the end of the reperfusion, blood samples were collected from the animals to measure serum M30 and M65 levels, which are markers of cell death, the @entity11 level, which is a marker of @entity0 , and the @entity6 ( @entity8 ) level, which is a marker of oxidative stress. The @entity5 size was evaluated as the ratio of the @entity5 area to the risk area. Apoptotic activation was assessed by @entity10 immunostaining and a TUNEL assay. @entity9 and NAC, either alone or in combination, significantly reduced serum @entity8 levels, @entity5 area and apoptotic activity compared to those observed in saline group. Interestingly, the @entity5 area was more smaller in @entity9 (3 and 5  mg/kg) injected groups (9.72      1.3% and 9.96      2.3%) than those observed in NAC (50 and 150  mg/kg) (16.1      2.5% and 19.1      2.14%) or @entity9 (5  mg/kg)- NAC (150  mg/kg) combination groups (16.9      1.6%). However, the apoptotic activity was reduced more significantly in the combination of @entity9 (5  mg/kg)-NAC (50  mg/kg) compared to @entity9 -only group. Neither @entity9 or NAC treatments nor the combination of the drugs significantly affected serum M30, M65 and @entity11 levels. CONCLUSION: Intravenous NAC and @entity9 administration decreased oxidative stress, @entity5 area and apoptotic activity in a @entity1 model of IR. Although the combination treatment was more effective in reducing the apoptotic activity than either treatment groups alone, @entity9 treatment was more successful in reducing the @entity5 area than NAC or combination treatments. Present results suggest that, in addition to mechanical attempts to secure myocardial reperfusion, the use of @entity9 and NAC may help to reduce IR injury.

title: Effective inhibition of cardiomyocyte apoptosis through the combination of XXXX and @entity4 in a @entity1 model of @entity3 and reperfusion injury.

answer: @entity7


abstract: OBJECTIVE: Apoptosis is the early and predominant form of cell death in infarcted myocardia. The aim of the study was to investigate the effects of @entity7 ( @entity9 ) and @entity4 (NAC), used alone or in combination, on oxidative stress, @entity5 size, and @entity2 -reperfusion (IR)-induced cardiomyocyte apoptosis in a @entity1 model of @entity3 . METHODS AND RESULTS: Myocardial IR was established by ligating an area under the left main coronary artery for 30  min followed by 3  h of reperfusion. Saline (1  ml/kg), NAC (50, 150  mg/kg), or @entity9 (3, 5  mg/kg) was intravenously injected during the middle of the @entity2 period. At the end of the reperfusion, blood samples were collected from the animals to measure serum M30 and M65 levels, which are markers of cell death, the @entity11 level, which is a marker of @entity0 , and the @entity6 ( @entity8 ) level, which is a marker of oxidative stress. The @entity5 size was evaluated as the ratio of the @entity5 area to the risk area. Apoptotic activation was assessed by @entity10 immunostaining and a TUNEL assay. @entity9 and NAC, either alone or in combination, significantly reduced serum @entity8 levels, @entity5 area and apoptotic activity compared to those observed in saline group. Interestingly, the @entity5 area was more smaller in @entity9 (3 and 5  mg/kg) injected groups (9.72      1.3% and 9.96      2.3%) than those observed in NAC (50 and 150  mg/kg) (16.1      2.5% and 19.1      2.14%) or @entity9 (5  mg/kg)- NAC (150  mg/kg) combination groups (16.9      1.6%). However, the apoptotic activity was reduced more significantly in the combination of @entity9 (5  mg/kg)-NAC (50  mg/kg) compared to @entity9 -only group. Neither @entity9 or NAC treatments nor the combination of the drugs significantly affected serum M30, M65 and @entity11 levels. CONCLUSION: Intravenous NAC and @entity9 administration decreased oxidative stress, @entity5 area and apoptotic activity in a @entity1 model of IR. Although the combination treatment was more effective in reducing the apoptotic activity than either treatment groups alone, @entity9 treatment was more successful in reducing the @entity5 area than NAC or combination treatments. Present results suggest that, in addition to mechanical attempts to secure myocardial reperfusion, the use of @entity9 and NAC may help to reduce IR injury.

title: Effective inhibition of cardiomyocyte apoptosis through the combination of @entity7 and XXXX in a @entity1 model of @entity3 and reperfusion injury.

answer: @entity4


abstract: OBJECTIVE: Apoptosis is the early and predominant form of cell death in infarcted myocardia. The aim of the study was to investigate the effects of @entity7 ( @entity9 ) and @entity4 (NAC), used alone or in combination, on oxidative stress, @entity5 size, and @entity2 -reperfusion (IR)-induced cardiomyocyte apoptosis in a @entity1 model of @entity3 . METHODS AND RESULTS: Myocardial IR was established by ligating an area under the left main coronary artery for 30  min followed by 3  h of reperfusion. Saline (1  ml/kg), NAC (50, 150  mg/kg), or @entity9 (3, 5  mg/kg) was intravenously injected during the middle of the @entity2 period. At the end of the reperfusion, blood samples were collected from the animals to measure serum M30 and M65 levels, which are markers of cell death, the @entity11 level, which is a marker of @entity0 , and the @entity6 ( @entity8 ) level, which is a marker of oxidative stress. The @entity5 size was evaluated as the ratio of the @entity5 area to the risk area. Apoptotic activation was assessed by @entity10 immunostaining and a TUNEL assay. @entity9 and NAC, either alone or in combination, significantly reduced serum @entity8 levels, @entity5 area and apoptotic activity compared to those observed in saline group. Interestingly, the @entity5 area was more smaller in @entity9 (3 and 5  mg/kg) injected groups (9.72      1.3% and 9.96      2.3%) than those observed in NAC (50 and 150  mg/kg) (16.1      2.5% and 19.1      2.14%) or @entity9 (5  mg/kg)- NAC (150  mg/kg) combination groups (16.9      1.6%). However, the apoptotic activity was reduced more significantly in the combination of @entity9 (5  mg/kg)-NAC (50  mg/kg) compared to @entity9 -only group. Neither @entity9 or NAC treatments nor the combination of the drugs significantly affected serum M30, M65 and @entity11 levels. CONCLUSION: Intravenous NAC and @entity9 administration decreased oxidative stress, @entity5 area and apoptotic activity in a @entity1 model of IR. Although the combination treatment was more effective in reducing the apoptotic activity than either treatment groups alone, @entity9 treatment was more successful in reducing the @entity5 area than NAC or combination treatments. Present results suggest that, in addition to mechanical attempts to secure myocardial reperfusion, the use of @entity9 and NAC may help to reduce IR injury.

title: Effective inhibition of cardiomyocyte apoptosis through the combination of @entity7 and @entity4 in a XXXX model of @entity3 and reperfusion injury.

answer: @entity1


abstract: OBJECTIVE: Although lipid crystals (LCs) have received attention as a causative factor of @entity2 , the mechanisms by which they increase plaque vulnerability are unknown. We examined whether solid-state LCs physically affect the adjacent extracellular matrix (ECM) using a combination of multimodal nonlinear optical (MNLO) imaging and @entity4 ( @entity4 ). METHODS: The changes of ECMs affected by lipids in @entity3 arteries in @entity5 -deficient @entity0 (n  =  32) fed a high-fat diet for 20-30 weeks were micro-anatomically visualized by a 3D MNLO imaging platform including CARS for lipids, TPEF for @entity6 , and SHG for collagen. RESULTS AND CONCLUSION: The TPEF signal of @entity6 was increased at the peripheral regions of LCs (<10   m) compared with foam cell regions. In order to confirm the increase of @entity6 , biochemical assay (western blot) was performed. The protein level of @entity6 was increased approximately 2.25-fold (p  =  0.024) in LC-rich arteries. Under the hypothesis that the increase of @entity6 resulted from the mechanical stimulus from solid-state LCs, MNLO images were subjected to @entity4 to simulate the displacement according to the expanding magnitude of the vessel during cardiac cycles. We found that microscale focal stress was increased specifically around the LCs. These @entity4 results corresponded with the increase of @entity6 observed by TPEF. These data suggest that LCs mechanically stimulate the adjacent ECM to alter the composition of ECM and cause vessel remodeling. The combination of MNLO imaging and @entity4 has great potential to verify the mechanical predictions in @entity1 .

title: Lipid crystals mechanically stimulate adjacent extracellular matrix in advanced XXXX plaques.

answer: @entity3


abstract: PURPOSE: The purpose of this study is to assess risk and time trends of newly recorded @entity2 and @entity1 in cases with @entity3 . METHODS: We conducted a matched incident cohort study (1996-2010) among @entity0 satisfying at least one of the following: 1) diagnosis of @entity3 on at least 2 visits within a 2-year period by a nonrheumatologist physician; or 2) diagnosis of @entity3 on at least one visit by a rheumatologist or from hospitalization; as well as receiving no prior @entity3 diagnosis between 1990 and 1995. Ten controls were matched by birth year, sex, and calendar year of exposure from the general population for each case. Incident @entity2 , @entity1 , and @entity2 or @entity1 was recorded from hospital or death certificates. We estimated incidence rate ratios and hazard ratios (HRs) after adjusting for confounders. RESULTS: Among 1239 individuals with @entity3 and no history of @entity2 (83% female, 56 years old), the incidence rate for @entity2 was 13.0/1000 @entity0 -years vs 4.1/1000 @entity0 -years in the comparison cohort. The incidence rate for @entity1 was 8.0/1000 @entity0 -years vs 3.7/1000 among controls. The adjusted HRs were 3.49 (95% confidence interval [CI], 2.52-4.83) and 2.35 (95% CI, 1.59-3.48) for @entity2 and @entity1 , respectively. For @entity2 and @entity1 , the risk was highest within the first year following diagnosis (HR 8.95; 95% CI, 5.43-14.74 and HR 5.25; 95% CI, 2.90-9.53, respectively). CONCLUSION: This large general population-based study indicates an increased risk of @entity2 and @entity1 in @entity0 with @entity3 , especially within the first year of diagnosis.

title: Early Cardiovascular Disease After the Diagnosis of XXXX .

answer: @entity3


abstract: Formation of nonextractable residue was widely observed as a sink of @entity9 ( @entity8 ) in soil. However, the mechanisms by which @entity8 binds to soil organic matter remain unclear. In this study, we demonstrated that neucleophilic substitution could serve an important pathway causing @entity8 sequestration. The @entity0 bonded to the @entity6 in @entity8 molecule is partially positively charged due to the strong electronegativity of @entity6 and is susceptible to the attack of nucleophiles such as @entity7 . Since @entity10 are relatively rare in natural soils, @entity3 /peptides were hypothesized to act as the main nucleophiles in real environment. However, substantially @entity8 transformation was only observed in the presence of those species containing @entity2 functionality. Thus, we speculated that it was the @entity2 group in @entity3 /peptides acting as the nucleophile. @entity4 in @entity3 was in fact not an active nucleophile toward @entity8 . In addition to the @entity1 -containing @entity3 , other @entity2 compounds, and @entity5 were also proved to be reactive to @entity8 . Thus, the sequestration potential of @entity8 probably correlates to the availability of @entity2 compounds in soil.

title: Nucleophilic substitution as a mechanism of XXXX sequestration in soil.

answer: @entity9


abstract: UNASSIGNED: Agents that target microtubule (MT) dynamics have been used extensively for the treatment of @entity0 ( @entity0 ). Among these agents are @entity5 (solvent-based @entity3 [sb- @entity3 ], @entity2 , and nab- @entity3 ) and non- @entity5 , such as eribulin and @entity6 . Although these agents have been approved for the treatment of @entity0 , questions regarding the ideal agent, regimen (single agent vs. combination vs. sequential), and schedule still remain. This systematic review examined pivotal trials for @entity5 , eribulin, and @entity6 as well as first-line @entity4 trials in @entity0 . Only randomized trials that enrolled  >=  100 @entity1 were included. Publications on combination regimens with targeted agents were excluded unless they also included a comparison between nontargeted regimens. The studies were grouped into @entity4 versus @entity4 , sb- @entity3 versus non- @entity4 , and @entity2 versus non- @entity4 regimens. In @entity4 versus @entity4 comparisons, the efficacy of sb- @entity3 and @entity2 appeared similar, nab- @entity3 every 3 weeks (q3w) appeared superior to sb- @entity3 q3w, and weekly nab- @entity3 appeared superior to @entity2 . In general, @entity4 regimens demonstrated higher overall response rates (ORRs) versus non- @entity4 regimens; however, only 2 trials demonstrated longer overall survival (OS) for @entity4 regimens. @entity5 will likely continue to be used in earlier lines of therapy, whereas eribulin and @entity6 may be more appropriate for later lines of treatment. Ongoing research may identify biomarkers that could help in selecting the appropriate MT-targeted agent for a given @entity1 .

title: Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting XXXX in Perspective.

answer: @entity5


abstract: OBJECTIVE: The aim of the study was to identify genetic variants predisposing to primary hip and @entity1 ( @entity0 ) in a sample of Finnish families. METHODS: Genome wide analysis was performed using 15 independent families (279 individuals) originating from Central Finland identified as having multiple individuals with primary hip and/or knee @entity0 . Targeted re-sequencing was performed for three samples from one 33-member, four-generation family contributing most significantly to the LOD score. In addition, exome sequencing was performed in three family members from the same family. RESULTS: Genome wide linkage analysis identified a susceptibility locus on chromosome 2q21 with a multipoint LOD score of 3.91. Targeted re-sequencing and subsequent linkage analysis revealed a susceptibility insertion variant @entity4 . It locates in a predicted strong enhancer element region with maximum LOD score 3.42 under dominant model of inheritance. Insertion creates a recognition sequence for @entity3 and @entity2 transcription factors. Their DNA-binding affinity is highly increased in the presence of A-allele compared to wild type null allele. CONCLUSION: A potentially novel functional @entity0 susceptibility variant was identified by targeted re-sequencing. This variant locates in a predicted regulatory site and creates a recognition sequence for @entity3 and @entity2 transcription factors that are predicted to play a significant role in articular cartilage homeostasis.

title: Targeted re-sequencing of linkage region on 2q21 identifies a novel functional variant for hip and XXXX .

answer: @entity1


abstract: UNASSIGNED: @entity0 ( @entity0 ) is an increasingly common disease of the small intestine that occurs in genetically susceptible subjects by ingestion of cereal gluten proteins. Gluten is highly abundant in the modern diet and well tolerated by most individuals. In @entity0 , however, an erroneous but highly specific, adaptive immune response is mounted toward certain parts of the gluten proteome. The resulting intestinal destruction is reversible and resolved upon removal of gluten from the diet. Post-translational modification (deamidation) of gluten peptides by @entity2 ( @entity2 ) is essential for the peptides to act as HLA-DQ-restricted T-cell antigens. Characteristically, deamidated gluten and the self-protein @entity2 both become targets of highly disease specific B-cell responses. These antibodies share several peculiar characteristics despite being directed against vastly different antigens, which suggests a common mechanism of development. Importantly, no clear function has been ascribed to the antibodies and their contribution to disease may relate to their function as antigen receptors of the B cells rather than as soluble immunoglobulins. Adaptive immunity against gluten and @entity2 appears not to be sufficient for establishment of the disease lesion, and it has been suggested that stress responses in the intestinal epithelium are essential for the development of full-blown disease and @entity1 . In this review we will summarize current concepts of the immune pathology of @entity0 with particular focus on recent advances in our understanding of disease specific B-cell responses.

title: XXXX : Autoimmunity in response to food antigen.

answer: @entity0